SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

08 Aug 2022 Evaluate
The sales moved up 32.46% to Rs. 2323.32 millions for the June 2022 quarter as compared to Rs. 1754.02 millions during the year-ago period.Net profit surges 96.79% to Rs. 201.55  millions  from Rs. 102.42 millions in the quarter ended June 2022.OP of the company witnessed a marginal growth to 320.78 millions from 185.30 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 2323.32 1754.02 32.46 2323.32 1754.02 32.46 8056.00 8135.63 -0.98
Other Income 41.14 28.99 41.91 41.14 28.99 41.91 147.58 128.41 14.93
PBIDT 320.78 185.30 73.11 320.78 185.30 73.11 1009.33 1483.12 -31.95
Interest 1.86 2.66 -30.08 1.86 2.66 -30.08 9.47 10.93 -13.36
PBDT 318.92 182.64 74.62 318.92 182.64 74.62 999.86 1472.19 -32.08
Depreciation 45.92 47.61 -3.55 45.92 47.61 -3.55 169.49 201.26 -15.79
PBT 273.00 135.03 102.18 273.00 135.03 102.18 830.37 1270.93 -34.66
TAX 71.45 32.61 119.10 71.45 32.61 119.10 214.43 337.90 -36.54
Deferred Tax -5.29 -9.06 -41.61 -5.29 -9.06 -41.61 -11.86 -10.38 14.26
PAT 201.55 102.42 96.79 201.55 102.42 96.79 615.94 933.03 -33.98
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 13.81 10.56 30.69 13.81 10.56 30.69 12.53 18.23 -31.27

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×